Castle Biosciences - CSTL STOCK NEWS

Castle Biosciences, Inc. announced new data supporting the DecisionDx-SCC test in patients with high-risk SCC tumors on the head and neck will be shared at the ACMS Annual Meeting. The test significantly improves prediction accuracy of metastatic events, aiding in risk-appropriate surveillance and treatments.

Castle Biosciences, Inc. (Nasdaq: CSTL) reported a 74% increase in Q1 2024 revenue over Q1 2023, reaching $73 million. Full-year revenue guidance for 2024 was raised to $255-265 million. The company delivered strong financial and operational results, showcasing growth in various test reports. Castle Biosciences continues to develop evidence supporting the clinical utility of its tests, with recent studies demonstrating potential healthcare savings and improved patient outcomes. The company's positive momentum in Q1 sets a solid foundation for continued success throughout the year.

Castle Biosciences, Inc. (Nasdaq: CSTL) kicks off Skin Cancer Awareness Month by supporting various initiatives. The company collaborates with IMPACT Melanoma to honor the City of Friendswood's designation as a Sun Safe Leadership Model City. The Sun Safe Leadership initiative includes programs like free sunscreen dispensers, portable shade tents, prevention education, and protective clothing for outdoor workers. Castle Biosciences partners with various organizations to raise awareness, support fundraising events, and provide education during Skin Cancer Awareness Month.

Castle Biosciences, Inc. (CSTL) will release its first-quarter financial results on May 2, 2024. A conference call and webcast will be held to discuss the results. Investors can access the webcast via the company's website or phone. International dial-in numbers are also available.

Castle Biosciences, Inc. (Nasdaq: CSTL) supports Esophageal Cancer Awareness Month by collaborating with key programs and initiatives to advance research, prevention, and education. The Company partners with Esophageal Cancer Action Network, Gastro Broadcast podcast, and EndoscopyNow to promote awareness and provide holistic support for patients and the GI professional community. Castle's prognostic risk-stratification test, TissueCypher®, aims to predict progression to high-grade dysplasia or esophageal cancer.

Castle Biosciences, Inc. (CSTL) announces its CFO, Frank Stokes, being selected as a Top 25 CFO of Houston for the second consecutive year. Stokes is recognized for his financial leadership and contribution to the company's growth.

Castle Biosciences, Inc. presents new data at EADO Congress showing DecisionDx-Melanoma and DecisionDx-SCC tests improve clinical decision-making and reduce costs. The tests accurately stratify patients with melanoma and squamous cell carcinoma, guiding treatment plans and reducing unnecessary procedures.

Castle Biosciences, Inc. (CSTL) is set to present at the 23rd Annual Needham Virtual Healthcare Conference, offering a company overview on April 9, 2024. The presentation will be available via live audio webcast on the company's website, with a replay option post-event.

Castle Biosciences, Inc. (CSTL) appoints Rodney Cotton to its board of directors, bringing extensive leadership experience from Roche Diagnostics. Mara G. Aspinall will not stand for re-election. Cotton's background includes financial turnarounds, global healthcare leadership, and COVID-19 response initiatives.